生命科学资讯

Investors load Corxel with $287M for a ‘differentiated’ obesity pill

Bristol Myers buys into Janux’s ‘masked’ T cell engagers

FDA lays out new path to speed development of multiple myeloma drugs

BioMarin vets form Mendra to ‘modernize’ rare disease drug development

Corvus shares nearly triple on positive data for eczema pill

J&J eyes $100B in sales amid gains for cancer, immune drugs

Valneva to withdraw Chikungunya vaccine from US amid safety woes

GSK to buy Rapt in $2.2B deal for food allergy drug

Moderna cancer vaccine holds up; IO Biotech considers a sale

Kailera’s Ron Renaud on how a China-linked startup can compete in obesity

The patient retention crisis is happening before enrollment even begins

When every day counts: Building CRO partnerships on a foundation of trust, care and precision

Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading

On biotech’s biggest stage, renewed excitement gets a stress test

Trump unveils healthcare affordability plan

Tecvayli tops standard drugs in early multiple myeloma, J&J says

Oxford Biomedica confirms takeover talks with biotech investor EQT

Boston Scientific to acquire Penumbra for $14.5B

JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view

Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill